BETHESDA, Md., July 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI - News), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it intends to offer shares of its common stock in a public offering. Piper Jaffray & Co. is acting as the sole book running manager, with RBC Capital Markets as co-manager in this offering. The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission on June 19, 2009, which became effective on July 2, 2009. A prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission.
